All news

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, took part in the EUROSPINE 2024 Congress, Europe’s leading spine conference, held from October 2 to 4, in Vienna, Austria. During the event, which brought together more than 3,500 spine surgeons and professionals from all over the world, Spineway enjoyed a prime location in the heart of the Messe Wien congress center, making its stand a must see for all congress attendees.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, recorded an excellent third quarter in 2024, with revenue of €2.6 million, representing purely organic growth (excluding change in the scope of consolidation) of 24% compared with the previous year. As a result, ninemonth revenue was €9.1 million, an increase of 21% on 2023.

Spineway, a specialist in innovative implants for the treatment of severe spinal pathologies, continues its organic growth (without scope effect) and achieves a turnover of €6.5 million for the first half of 2024, up 20% compared to S1 2023. The gross margin remains at a normative level of 69%, stable compared to the end of 2023 and in line with the Group's forecasts.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 24th AMCICO (Asociación Mexicana de Cirujanos de Columna) congress in Cancún from September 4 to 8, 2024. This annual congress of spine surgeons is a flagship event for the spine surgery sector in Mexico, the largest market in Central and Latin America.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is taking part in the Sociedad Iberolatinoamericana de Columna (SILACO) Congress in Mexico from July 24 to 27, 2024 with two local partners, Spinemed and Mava. As a Gold Sponsor of this major event in Latin America, Spineway will increase its visibility among spine surgeons and professionals in this strategic region.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, continued its entirely organic growth (no change in scope) in the second quarter of 2024, recording revenue of €3.4 million. This good performance brings half-year revenue to €6.5 million, representing growth of 20% compared with H1 2023. As a reminder, organic growth was 12% in H1 2023,1 reflecting the Group’s positive trajectory.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, organized a hands-on training workshop entitled “Hands-on Total Disc Replacement featuring ESP technology” at the Institut de Recherche contre les Cancers de l’Appareil Digestif (IRCAD) in Strasbourg on June 28, 2024. During the event, Spineway’s ESP prostheses (cervical and lumbar) were presented to 25 surgeons and professionals, with a presentation of the products, their indications and two surgical approach sessions.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it participated in the 38th edition of GEER, the annual congress of the Spanish Spine Society, held in Malaga in May.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, participated in the 4th SMISS Asia Pacific congress, dedicated to minimally invasive surgery, held in Hong Kong on June 13 and 14. Spineway was a Bronze Sponsor of the event, where the Group presented its ESP (cervical and lumbar) prostheses through demonstrations and scientific papers, highlighting the growing interest in cervical and lumbar prostheses in this historic region for the Group. This annual congress attracts surgeons from many Asian countries and has allowed Spineway to consolidate its presence, particularly in Hong Kong, where it has been marketing ESP disc prostheses for over seven years.